Tong Luo

446 total citations
10 papers, 312 citations indexed

About

Tong Luo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tong Luo has authored 10 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Tong Luo's work include Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (3 papers) and HER2/EGFR in Cancer Research (2 papers). Tong Luo is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (3 papers) and HER2/EGFR in Cancer Research (2 papers). Tong Luo collaborates with scholars based in United States, China and Switzerland. Tong Luo's co-authors include Dennis J. Slamon, Neil A. O’Brien, Dylan Conklin, Sara A. Hurvitz, Samit Hirawat, Ronald Linnartz, Erika von Euw, Ondrej Kalous, Emmanuelle di Tomaso and Richard S. Finn and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Tong Luo

10 papers receiving 304 citations

Peers

Tong Luo
Michela Palleschi Italy
IA Mayer United States
NU Lin United States
Sun Min Lim South Korea
Mark T. J. van Bussel Netherlands
Sheida Hayati United States
M. Campone France
S. Ogawa Japan
Mengxi Ge China
Morana Vojnic United States
Michela Palleschi Italy
Tong Luo
Citations per year, relative to Tong Luo Tong Luo (= 1×) peers Michela Palleschi

Countries citing papers authored by Tong Luo

Since Specialization
Citations

This map shows the geographic impact of Tong Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tong Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tong Luo more than expected).

Fields of papers citing papers by Tong Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tong Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tong Luo. The network helps show where Tong Luo may publish in the future.

Co-authorship network of co-authors of Tong Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Tong Luo. A scholar is included among the top collaborators of Tong Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tong Luo. Tong Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Chen, Xinru, Jinyu Wang, Chao Wu, et al.. (2024). Associations of objective sleep duration and physical activity with risk of heart failure: A prospective cohort study. General Hospital Psychiatry. 90. 141–149. 1 indexed citations
2.
Yu, Zhongyuan, Tong Luo, Cheng‐Rong Tan, et al.. (2024). Oral antioxidant edaravone protects against cognitive deficits induced by chronic hypobaric hypoxia at high altitudes. Translational Psychiatry. 14(1). 415–415. 3 indexed citations
3.
4.
O’Brien, Neil A., Martina S.J. McDermott, Dylan Conklin, et al.. (2020). Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research. 22(1). 89–89. 87 indexed citations
5.
O’Brien, Neil A., Martina S.J. McDermott, Dylan Conklin, et al.. (2019). Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models. Cancer Research. 79(13_Supplement). 3825–3825. 1 indexed citations
6.
O’Brien, Neil A., Dylan Conklin, Richard P. Beckmann, et al.. (2018). Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics. 17(5). 897–907. 80 indexed citations
7.
O’Brien, Neil A., Dylan Conklin, Tong Luo, et al.. (2017). Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy. Cancer Research. 77(13_Supplement). 4150–4150. 4 indexed citations
8.
O’Brien, Neil A., Dylan Conklin, Tong Luo, et al.. (2016). Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer. Cancer Research. 76(14_Supplement). 2828–2828. 1 indexed citations
9.
O’Brien, Neil A., Tong Luo, Erika von Euw, et al.. (2014). Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research. 20(13). 3507–3520. 93 indexed citations
10.
O’Brien, Neil A., Emmanuelle di Tomaso, Raul Ayala, et al.. (2014). Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Research. 74(19_Supplement). 4756–4756. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michela Palleschi Breakdown of academic impact, for papers by IA Mayer Breakdown of academic impact, for papers by NU Lin Breakdown of academic impact, for papers by Sun Min Lim Breakdown of academic impact, for papers by Mark T. J. van Bussel Breakdown of academic impact, for papers by Sheida Hayati Breakdown of academic impact, for papers by M. Campone Breakdown of academic impact, for papers by S. Ogawa Breakdown of academic impact, for papers by Mengxi Ge Breakdown of academic impact, for papers by Morana Vojnic
Rankless by CCL
2026